Novartis in the zone
Novartis' hypertension programs have improved compliance by 50 percent, the firm reports during its Q4 earnings call Jan. 18. Novartis has enrolled 500,000 patients worldwide in its "BP Zone" compliance initiative, a part of its "category captainship" strategy to enhance its leadership position in the hypertension market. Novartis is offering patients assistance with managing blood pressure by offering blood pressure monitors, information services and an educational Web site (1"The Pink Sheet" Oct. 30, 2006, p. 13). "We believe based on our analysis that those patients which were enrolled and stayed on the program, the compliance rate was increased by 50 percent," CEO Thomas Ebeling says. "That's one of the reasons why our market share in the U.S. has recovered"...
You may also be interested in...
Nearly a year after introducing its "category captainship" strategy to enhance its leadership position in the market, Novartis is reporting its most successful quarter in the hypertension market
Formycon and partner Bioeq have offered further details on timing for the submission of their FYB201 proposed ranibizumab biosimilar version of Lucentis in Europe, the US and elsewhere.
The fresh cash injection will fund Phase II studies evaluating the UK firm's 12-month treatment for diabetic macular edema.